---
title: "ImmuneOnco files HKEX next-day disclosure return after share repurchase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292068983.md"
description: "ImmuneOnco filed a next-day disclosure return with the HKEX regarding share repurchases. On July 8, 2026, the company bought back 55,600 H shares for treasury at a total cost of HKD 201,378, priced between HKD 3.58 and HKD 3.67 per share. No shares were cancelled. Consequently, issued shares excluding treasury decreased to 418,754,305, while treasury shares increased to 1,723,000."
datetime: "2026-07-08T12:33:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292068983.md)
  - [en](https://longbridge.com/en/news/292068983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292068983.md)
---

# ImmuneOnco files HKEX next-day disclosure return after share repurchase

-   ImmuneOnco repurchased 55,600 H shares on July 8, 2026 for treasury, paying HKD 201,378 at HKD 3.58–HKD 3.67. \* No shares were repurchased for cancellation; total repurchased/cancelled shares: 55,600. \* Issued shares excluding treasury fell to 418,754,305; treasury shares rose to 1,723,000. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260708-12238293), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01541.HK](https://longbridge.com/en/quote/01541.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [ImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease](https://longbridge.com/en/news/292272907.md)
- [ImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection](https://longbridge.com/en/news/290219823.md)
- [Ascletis Pharma files HKEX next-day disclosure return on share repurchase cancellation](https://longbridge.com/en/news/293323275.md)
- [Repsol targets capital cut via cancellation of shares bought in EUR 500 million buyback](https://longbridge.com/en/news/293565218.md)
- [Instructure survey shows 90% of higher education students use AI in class](https://longbridge.com/en/news/293347497.md)